Anumigilimab

CAS No. 2416593-08-1

Anumigilimab( —— )

Catalog No. M36769 CAS No. 2416593-08-1

Anumigilimab (CSL-324) is a fully human therapeutic anti-G-CSFR antibody with potential anti-tumor activity for the study of inflammation.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 375 Get Quote
5MG 586 Get Quote
10MG 834 Get Quote
25MG 1224 Get Quote
50MG 1647 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Anumigilimab
  • Note
    Research use only, not for human use.
  • Brief Description
    Anumigilimab (CSL-324) is a fully human therapeutic anti-G-CSFR antibody with potential anti-tumor activity for the study of inflammation.
  • Description
    Anumigilimab (CSL-324) is an humanized IgG2a mAb against human granulocyte colony-stimulating factor (G-CSF) receptor. Anumigilimab can be used for increasing numbers of neutrophils at sites of inflammation.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Tyrosine Kinase
  • Target
    CSF1R
  • Recptor
    c-Fms
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2416593-08-1
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Markota ?agalj A, et al. New and Emerging Targeted Therapies for Hidradenitis Suppurativa. Int J Mol Sci. 2022 Mar 29;23(7):3753. ?
molnova catalog
related products
  • Pexidartinib

    An oral-active, BBB-penatrant, potent mutil-targeted RTK inhibitor of CSF-1R, Kit, and Flt3 with IC50 of 20 nM, 10 nM and 160 nM, respectively.

  • c-Fms-IN-2

    c-Fms-IN-2 is an inhibitor of FMS kinase (IC50: 0.024 μM).

  • JNJ-6204

    JNJ-6204 is a dual inhibitor of CSNK1D (IC50 = 2.3 nM) and CSNK1E (IC50 = 137 nM).